ARUP Institute for Clinical & Experimental Pathology®

Created in 1996, the ARUP Institute for Clinical and Experimental Pathology® seeks to expand the quantity, quality, and utility of laboratory medicine. Since its inception, the institute has developed approximately 620 tests that ARUP now performs in-house. Of these 620 tests, more than 400 were developed by institute scientists, while more than 200 others were improved and validated so that ARUP could perform them in-house rather than continue to refer them out. Moreover, ARUP research scientists have shared their knowledge, experience, and new developments with the scientific community by publishing more than 1,600 original peer-reviewed research publications in leading journals.

The institute’s mission is to be at the forefront of innovative research and development in clinical and experimental laboratory medicine and to continually contribute to the profession.

Research Focus

The institute's focus covers the spectrum of medical laboratory medicine:

Executive Directors

Julio Delgado, MD, MS
Co-Executive Director
(801) 583-2787

 

Sherrie L. Perkins, MD, PhD
Co-Executive Director
(801) 581-5854

Project Categories

The ARUP Institute for Clinical and Experimental Pathology® sponsors projects within four broad categories: creating new laboratory tests; improving current clinical laboratory tests; evaluating and critiquing tests, including alpha- and beta-site protocols; and conducting basic and clinical research projects. Research performed on human subjects is conducted under informed consent following the protocols approved by the University of Utah Institutional Review Board (IRB).


 

Recent Publications

Tebo AE. Antiphospholipid syndrome and the relevance of antibodies to negatively charged phospholipids in diagnostic evaluation. Lupus 2014;23(12):1313–6.

Grenache DG, Heichman KA, Werner TL, Vucetic Z. Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass. Clin Chimica Acta 2014;438C:358–63.

Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 2014;89(10):1017.

Okal A, Matissek KJ, Matissek SJ, Price R, Salama ME, Janát-Amsbury MM, Lim CS. Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model. Gene Ther 2014;21(10):903–12.

Petrides AK, Moskowitz J, Johnson-Davis KL, Jannetto PJ, Langman LJ, Clarke W, Marzinke MA. The development and validation of a turbulent flow-liquid chromatography-tandem mass spectrometric method for the simultaneous quantification of citalopram, sertraline, bupropion and hydroxybupropion in serum. Clin Biochem 2014;47(15):73–9.